(LNTH) Lantheus Holdings, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LNTH) Lantheus Holdings, Inc. Complete Analysis Pack
Validate Every Claim with the Complete Sources File
This Lantheus Holdings, Inc. SWOT Analysis provides a concise, company-specific breakdown of strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions; the page already includes a real preview/sample of the analysis so you can review style and substance before buying. Purchase the full version to download the complete, ready-to-use SWOT report.
Strengths
10 diagnostic products
Lantheus Holdings, Inc. sells 10 diagnostic products across ultrasound contrast, nuclear medicine, and PET, so it is not tied to one asset or one workflow. That breadth supports use in hospitals, clinics, and radiopharmacies, while PYLARIFY and DEFINITY anchor reach across major imaging channels. A wider portfolio also helps reduce product-specific demand swings.
PYLARIFY in prostate cancer
PYLARIFY is a leading PSMA PET imaging agent for recurrent or metastatic prostate cancer, a market tied to the 1 in 8 lifetime risk of prostate cancer in men. Its ability to detect bone, lymph node, and soft tissue metastases gives Lantheus a strong edge in precision diagnostics and in one of oncology’s largest imaging opportunities.
Established since 1956
Founded in 1956, Lantheus Holdings, Inc. brings nearly 70 years of operating history as of July 2026. That long run supports physician trust, deeper manufacturing know-how, and stronger regulatory discipline across imaging and radiopharmaceutical products. It also shows the Company has stayed resilient through multiple healthcare, pricing, and reimbursement cycles.
2 therapeutic products
AZEDRA and RELISTOR give Lantheus Holdings, Inc. 2 marketed therapeutic products beyond diagnostics, which helps balance a business that still leans on imaging. In FY2025, that broader mix can add recurring sales, longer product lifecycles, and closer ties with specialists treating complex cancer and GI disease.
2 therapies broaden revenue sources
Less reliance on diagnostics only
Supports specialist relationships
10 strategic partners
Lantheus Holdings, Inc. has 10 strategic partners, including NanoMab, Bausch Health, GE Healthcare, Curium, Bayer, CytoDyn, ROTOP, FUJIFILM, Regeneron, and POINT Biopharma. These alliances widen access to technology, manufacturing, and commercialization channels, which helps the Company move faster across multiple programs. Spreading development work across 10 partners also lowers single-program risk and supports a broader pipeline.
10 strategic partners expand reach
Shared tech and manufacturing access
Commercialization support across markets
Risk spread across multiple programs
Lantheus’ Broad Imaging Mix Powers Oncology Growth
Lantheus Holdings, Inc. strength comes from its broad imaging mix: 10 products across ultrasound contrast, nuclear medicine, and PET. PYLARIFY is a leading PSMA PET agent, giving the Company a strong oncology foothold. Two marketed therapies, AZEDRA and RELISTOR, also reduce reliance on imaging alone. Ten strategic partners support reach, tech, and manufacturing.
| Metric | Value |
|---|---|
| Products | 10 |
| Therapies | 2 |
| Strategic partners | 10 |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Lantheus Holdings, Inc.’s business strategy
Editable Excel File
Delivers a quick SWOT snapshot for Lantheus Holdings, Inc. to simplify strategic decision-making and reduce analysis fatigue.
Reference Sources
Cites primary industry reports, FDA filings, company filings, and trusted benchmarks to speed due diligence and validate key Lantheus assumptions.
Weaknesses
High dependence on imaging markets
Lantheus’s revenue is still heavily tied to diagnostic imaging and radiopharmaceutical use, so procedure volumes matter a lot. If hospital capital spending tightens or imaging reimbursement weakens, growth can slow fast. In its latest reported year, the company still derived the vast majority of sales from imaging-related products, leaving it exposed to any drop in scan demand.
Concentrated prostate cancer exposure
PYLARIFY is Lantheus Holdings, Inc.’s core growth engine, and PYLARIFY AI also sits inside prostate cancer, so the Company is heavily tied to one indication and one imaging pathway. In 2024, PYLARIFY revenue was about $1.0 billion, a very large share of total Company sales. If prostate cancer imaging standards shift, a major slice of Lantheus Holdings, Inc.’s growth can move fast.
Limited therapeutic scale
Lantheus Holdings, Inc.’s therapeutic business is still tiny next to its imaging franchise, which drove most of its roughly $1.3 billion revenue base in FY2024. AZEDRA and RELISTOR have not reached the scale of leading imaging assets like DEFINITY, so diversification stays thin. That leaves earnings more exposed to a few diagnostic products.
Pipeline execution risk
Lantheus Holdings, Inc. faces real pipeline execution risk because flurpiridaz F 18, 1095, LMI 1195, PYLARIFY AI, and leronlimab all depend on clean clinical, regulatory, and launch results. Even one delay or weak readout can hit future growth, especially after 2024 revenue reached about $1.4 billion and PYLARIFY remained the main cash engine. That makes pipeline misses a direct threat to the next leg of sales.
Five programs need successful execution.
Any delay can slow growth.
Negative data can cut expected value.
Complex radiopharmaceutical supply chain
Lantheus Holdings, Inc. relies on a tightly controlled radiopharmaceutical chain for TechneLite, Gallium-67, Thallium-201, and other products. Unlike small-molecule drugs, isotopes need specialized production, time-sensitive transport, and strict handling, so even a short outage can hit supply and trust.
- Specialized isotope manufacturing raises failure risk.
- Transport delays can cut usable product life.
- Supply hits can reduce customer confidence fast.
PYLARIFY Dependence Leaves Lantheus Exposed
Lantheus Holdings, Inc.’s main weakness is concentration: PYLARIFY brought in about $1.0 billion of 2024 revenue, or most of Company sales, so one prostate imaging asset drives results. The rest of the portfolio is much smaller, and pipeline bets still face clinical and launch risk. Its isotope supply chain also adds outage risk.
| Weakness | Data |
|---|---|
| Revenue mix | ~$1.4B FY2024 |
| PYLARIFY | ~$1.0B FY2024 |
| Diversification | Thin beyond imaging |
Preview Before You Purchase
Lantheus Holdings, Inc. Reference Sources
This preview reflects the real SWOT analysis document you'll receive upon purchase—professional, structured, and ready to use. The excerpt below is taken directly from the full Lantheus Holdings, Inc. report; buy now to unlock the complete, editable version with comprehensive strengths, weaknesses, opportunities, threats, and strategic implications.
Opportunities
PSMA PET expansion
PSMA PET keeps expanding as prostate cancer imaging gains wider use, and PYLARIFY is the main driver for Lantheus Holdings, Inc.; in 2024, PYLARIFY generated about $811 million in sales. More site adoption, smoother workflows, and broader clinical use can lift scan volume and repeat testing. That should widen patient access and keep utilization rising over time.
Flurpiridaz F 18 launch potential
Flurpiridaz F 18, FDA-approved in 2024 as Flyrcado for PET myocardial perfusion imaging, gives Lantheus a higher-value tool for assessing myocardial blood flow in coronary artery disease. With U.S. CAD affecting about 20 million adults, even modest uptake can expand the cardiac imaging franchise and add a premium diagnostic revenue stream.
AI software monetization
PYLARIFY AI can turn PSMA PET/CT scans into standardized quantitative outputs, which helps doctors compare results faster and more consistently. Because software scales with far lower marginal delivery cost than radiopharmaceutical doses, Lantheus Holdings, Inc. can add recurring digital revenue without the same supply-chain burden. That also deepens workflow lock-in around the PYLARIFY platform.
Neuroblastoma asset LMI 1195
LMI 1195 could give Lantheus entry into neuroblastoma, a rare cancer with about 700 to 800 new U.S. cases a year and roughly 15% of pediatric cancer deaths. If development succeeds, it would open a high-need oncology niche in children and adults, while also adding rare-disease and pediatric credibility. That matters because Lantheus is still anchored by imaging and needs new growth legs.
- Rare, high-need oncology market
- Targets children and adults
- Boosts pediatric credibility
- Expands beyond core imaging
Partnership-driven expansion
Lantheus posted about $1.3 billion of 2024 revenue, and partnerships can help it scale PET imaging faster without building every capability in-house. Major healthcare and pharma partners can add manufacturing capacity, imaging expertise, and global commercialization reach, which can speed launches and limit capital spend.
- Faster market reach through partner networks
- Shared manufacturing and imaging expertise
- Lower need for internal capex
Lantheus Growth: PYLARIFY Scale, Flyrcado Launch, and AI Upside
Lantheus Holdings, Inc. can grow by scaling PYLARIFY, which drove about $811 million of 2024 sales, and by pushing broader PSMA PET adoption. Flyrcado, approved in 2024, opens coronary imaging in a U.S. CAD market of about 20 million adults. PYLARIFY AI can add recurring software revenue, while LMI 1195 gives rare-disease upside. Partner deals can speed launches.
| Opportunity | Data point |
|---|---|
| PYLARIFY | $811M sales, 2024 |
| Flyrcado | FDA-approved, 2024 |
| U.S. CAD | ~20M adults |
Threats
Intense imaging competition
Intense imaging competition is a real threat for Lantheus Holdings, Inc. because GE Healthcare, Bayer, Curium, and FUJIFILM all have deep pockets and broad sales reach. In 2025, that kind of scale can push pricing lower, make contract wins harder, and squeeze market share. New imaging platforms can also reduce demand for legacy agents, so Lantheus has to keep proving clinical value fast.
Regulatory approval risk
Radiopharmaceutical approvals are slow and strict, with FDA reviews often taking 10-12 months after filing and Phase 3 trials usually enrolling hundreds of patients. Lantheus Holdings, Inc.'s 1095 and LMI 1195 could face delays, safety flags, or manufacturing issues, pushing launch plans back by years. Any non-approval would hit future sales growth and lower the pipeline's value.
Reimbursement pressure
Reimbursement pressure is a real threat for Lantheus Holdings, Inc. because PYLARIFY and other imaging tools depend on payer coverage and fair payment. If coverage tightens or rates fall, use can slow fast, especially in high-cost specialty diagnostics. In 2025, that risk matters more as payers keep pushing for lower spending and stricter prior authorization.
Supply chain and isotope disruption
Lantheus Holdings, Inc. depends on tightly timed isotope supply, cold-chain handling, and specialist manufacturing. The key risk is that many radiopharmaceutical inputs, like Mo-99 with a 66-hour half-life, lose usable activity fast, so even a short plant or transport break can cut dose availability and sales.
That makes supply shocks more damaging than in standard pharma: one missed shipment can disrupt scans the same day. If an upstream reactor, processing site, or courier network slips, Lantheus Holdings, Inc. can face lost revenue, backorders, and weaker customer trust.
- Isotope decay is time-sensitive
- Few qualified suppliers exist
- Short outages hit output fast
- Lost doses can mean lost sales
Clinical adoption uncertainty
Clinical adoption is still a risk for Lantheus Holdings, Inc.: PYLARIFY brought in $908.2 million of revenue in 2024, but new tools like PYLARIFY AI and pipeline assets still need broad physician buy-in. If clinicians keep older workflows or rival standards, uptake can lag and cut the return on R&D spend.
- PYLARIFY revenue: $908.2 million, 2024
- Adoption depends on physician workflow fit
- Slow uptake can depress R&D returns
Lantheus Faces Fierce Competition and Pipeline Delays
GE Healthcare, Bayer, Curium, and FUJIFILM keep pricing and share pressure high for Lantheus Holdings, Inc., while new imaging platforms can also reduce demand for older agents.
Radiopharmaceutical approvals stay slow and strict, so 1095 and LMI 1195 face delay, safety, and manufacturing risk that can push launches back.
PYLARIFY's $908.2 million 2024 revenue still depends on payer coverage, physician adoption, and time-sensitive isotope supply.
| Threat | Key data |
|---|---|
| Competition | GE Healthcare, Bayer, Curium, FUJIFILM |
| Pipeline risk | 1095, LMI 1195 |
| Commercial risk | PYLARIFY revenue: $908.2 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.